Advanced search
1 file | 1.49 MB Add to list

A Randomized Phase II Study of Nivolumab Plus Ipilimumab Versus Standard of Care in Previously Untreated and Advanced Non-Clear Cell Renal Cell Carcinoma (Suniforecast)

Author
Organization

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 1.49 MB

Citation

Please use this url to cite or link to this publication:

MLA
Ahrens, Marit, et al. “A Randomized Phase II Study of Nivolumab Plus Ipilimumab Versus Standard of Care in Previously Untreated and Advanced Non-Clear Cell Renal Cell Carcinoma (Suniforecast).” ONCOLOGY RESEARCH AND TREATMENT, vol. 43, Karger, 2020, pp. 226–226.
APA
Ahrens, M., Escudier, B., Boleti, E., Grimm, M.-O., Goupir, M. G., Barthelemy, P., … Bergmann, L. (2020). A Randomized Phase II Study of Nivolumab Plus Ipilimumab Versus Standard of Care in Previously Untreated and Advanced Non-Clear Cell Renal Cell Carcinoma (Suniforecast). In ONCOLOGY RESEARCH AND TREATMENT (Vol. 43, pp. 226–226). Basel: Karger.
Chicago author-date
Ahrens, Marit, Bernard Escudier, Ekaterini Boleti, Marc-Oliver Grimm, Marine Gross Goupir, Pilippe Barthelemy, Gwenaelle Gravis, et al. 2020. “A Randomized Phase II Study of Nivolumab Plus Ipilimumab Versus Standard of Care in Previously Untreated and Advanced Non-Clear Cell Renal Cell Carcinoma (Suniforecast).” In ONCOLOGY RESEARCH AND TREATMENT, 43:226–226. Basel: Karger.
Chicago author-date (all authors)
Ahrens, Marit, Bernard Escudier, Ekaterini Boleti, Marc-Oliver Grimm, Marine Gross Goupir, Pilippe Barthelemy, Gwenaelle Gravis, Jens Bedekes, Philipp Ivanyi, Andrej Panic, Stefanie Zschaebitz, Sylvie Neyrieru, Begona Mellado, Anika Biel, Tom Wadell, Jose Pablo Maroto, Margitta Retz, Martin Boegemann, Sylvie Rottey, John Haanen, Sjoukje Oosting, Daniel Castellano, Arndt Hartmann, and Lothar Bergmann. 2020. “A Randomized Phase II Study of Nivolumab Plus Ipilimumab Versus Standard of Care in Previously Untreated and Advanced Non-Clear Cell Renal Cell Carcinoma (Suniforecast).” In ONCOLOGY RESEARCH AND TREATMENT, 43:226–226. Basel: Karger.
Vancouver
1.
Ahrens M, Escudier B, Boleti E, Grimm M-O, Goupir MG, Barthelemy P, et al. A Randomized Phase II Study of Nivolumab Plus Ipilimumab Versus Standard of Care in Previously Untreated and Advanced Non-Clear Cell Renal Cell Carcinoma (Suniforecast). In: ONCOLOGY RESEARCH AND TREATMENT. Basel: Karger; 2020. p. 226–226.
IEEE
[1]
M. Ahrens et al., “A Randomized Phase II Study of Nivolumab Plus Ipilimumab Versus Standard of Care in Previously Untreated and Advanced Non-Clear Cell Renal Cell Carcinoma (Suniforecast),” in ONCOLOGY RESEARCH AND TREATMENT, 2020, vol. 43, pp. 226–226.
@inproceedings{8654995,
  author       = {Ahrens, Marit and Escudier, Bernard and Boleti, Ekaterini and Grimm, Marc-Oliver and Goupir, Marine Gross and Barthelemy, Pilippe and Gravis, Gwenaelle and Bedekes, Jens and Ivanyi, Philipp and Panic, Andrej and Zschaebitz, Stefanie and Neyrieru, Sylvie and Mellado, Begona and Biel, Anika and Wadell, Tom and Pablo Maroto, Jose and Retz, Margitta and Boegemann, Martin and Rottey, Sylvie and Haanen, John and Oosting, Sjoukje and Castellano, Daniel and Hartmann, Arndt and Bergmann, Lothar},
  booktitle    = {ONCOLOGY RESEARCH AND TREATMENT},
  issn         = {2296-5270},
  language     = {eng},
  pages        = {226--226},
  publisher    = {Karger},
  title        = {A Randomized Phase II Study of Nivolumab Plus Ipilimumab Versus Standard of Care in Previously Untreated and Advanced Non-Clear Cell Renal Cell Carcinoma (Suniforecast)},
  volume       = {43},
  year         = {2020},
}

Web of Science
Times cited: